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Abstract 
Background: Murine models of Alzheimer’s disease (AD) are mainly based on overexpression of pathologic amyloid 
precursor protein and/or presenilins. Those genes resemble underlying cause of early onset type of AD while about 
99 % of all human cases are to be characterized as sporadic, late onset. Appropriate animal models for this type of AD 
are still missing. We here investigated, if transnasal delivery of A-beta 42 peptides might serve to mimic pathological 
effects in mice.
Results: A-beta 42 peptides, used for the behavioral study, showed the expected dose-dependent toxicity in neur 
oblastoma cell line SH-SY5Y and were able to form higher molecular weight species in vitro. Upon delivery into nos-
trils of wild type mice, protein bands that might represent aggregation products of the exogenously applied human 
A-beta 42 were only observed in total brain homogenates from mice pre-treated with mannitol. By using TAMRA-
labeled A-beta 42 peptides we demonstrated, that transport throughout the brain was achieved already 1 h after 
administration. FVB/N mice treated with A-beta 42 for 3 days were significantly impaired in the cue-retention condi-
tion of the fear conditioning task as compared to controls whereas A-beta-treated C57B6/J mice were impaired in the 
context condition. In the Morris water maze test, these mice also displayed a delayed learning performance, indicated 
by significantly longer time to find the platform. Those deficits were also seen for memory performance in the probe 
trial as measured by number of crossings of the former platform position and time spent in the goal quadrant.
Conclusions: Existing AD mouse models are of genetic origin and need prolonged housing time before onset of 
pathology. Our short-term treatment induced learning and memory deficits via exogenous application of A-beta pep-
tides comparable to those observed for the transgenic animals. With the transnasal A-beta 42 treatment we present 
an approach to investigate purely A-beta related changes suitable as a model for symptoms of Alzheimer’s dementia 
(AD). Resulting behavioral deficits were indicative for familial type of Alzheimer’s disease as well as for the late onset 
variant.
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Background
Brain aging is probably a multifaceted process in which 
small deviations from homeostasis might already have 
deleterious outcome. Alzheimer’s disease (AD) is one of the 
major disorders of the human brain occurring in the elderly 
and aging is the most prominent risk factor assigned to 
the sporadic form (or late onset form, LOAD) of this type 
of dementia. To mimic such a complex progressive disor-
der in animal models is rather difficult (e.g. [1]). Within the 
last decades, several mouse and also rat models have been 
established for familial AD (FAD), mainly based on the 
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three genes that are involved in development of the subtype 
of the disease: single transgenic mice with either mutations 
in APP (amyloid precursor protein) or one of the preseni-
lins (PS1 or 2) reveal some of the disease criteria such as 
plaque deposition or memory deficits. Double, triple or 
even quintuple transgenic mice have been established 
with combination of each gene to overcome low intensity 
and long time frame of progression of pathological hall-
marks (for a characterization of 10 such models see: [2]). 
Adding mutated tau species in part completed the foot-
print of AD in the animal model [3]. Recently, a knock-in 
mouse with subtle overexpression of human BACE-1 has 
been described that seems to reflect certain characteristics 
of AD in a more physiological way than the multi-trans-
genic mice: while no monomeric A-beta was detectable, 
the toxic A-beta hexamer formed from endogenous APP 
cleavage products was observed and mice displayed cog-
nitive impairment that was intensified by aging [4]. Other 
researchers suggest e.g. crossbreeding of traditional AD 
mouse models with insulin desensitized mouse strains to 
end up with a more complete picture of the disease [5]. All 
these models face the drawback of the need for prolonged 
housing times for the occurrence of appropriate patho-
logical signs, production of non-transgenic littermates in 
case of heterozygous breeding and their origin by genetic 
manipulation. The latter might interfere with unforeseen 
metabolic or signaling pathways contributing to the result-
ing phenotype and a limited face validity with respect to 
late onset non familiar AD.
It is intensively discussed in the field, if A-beta pep-
tide overproduction or reduced degradation is the main 
impetus of sporadic AD development (e.g. [6]). However, 
acute intracerebroventricular (icv) injections of synthetic 
A-beta 42 oligomers impaired consolidation of the long-
term recognition memory [7]. Moreover, icv injection of 
the less toxic A-beta 40 species similarly impaired cogni-
tive function as measured by Morris water maze testing 
[8]. As stereotactic injection is an invasive manipulation 
that also needs expertise of the investigators, a more mild 
and easy to handle technique of A-beta delivery into the 
brain would be helpful. Transnasal delivery of peptides 
has been repeatedly described in literature to be of suc-
cess in mice (e.g. [9, 10]). This might be supported by the 
murine nasal cavity architecture featuring high surface 
area (e.g. [11]). To build up on that, the present investiga-
tion aimed at analyzing whether intranasal A-beta appli-
cation could serve as a less invasive, less stressful lesion 
model for late onset related beta-amyloid pathology.
Methods
Material
Human A-beta 42 (W. M. Keck Foundation Biotechnol-
ogy Resource Laboratory, Yale, UK) was prepared and 
purified as follows: 1 mg of lyophilized material was dis-
solved in 10 mM NH4OH and passed through a 0.22 µm 
filter (Ultrafree Durapore PVDF, Merck Millipore, 
Schwalbach, Germany) followed by 30  k filtration using 
Amicon devices (Merck Millipore, Schwalbach, Ger-
many). Protein concentration was calculated via absorb-
ance at 280  nm (Nanodrop, VWR International GmbH, 
Erlangen, Germany). Aliquots of the peptide were diluted 
1:2 with PBS and stored at −80  °C. N-ethylmaleimide 
(NEM) was purchased from Calbiochem (Merck, Darm-
stadt, Germany) and mannitol from Sigma Aldrich (St. 
Louis, MO, USA).
Cell culture and toxicity assays
The human neuroblastoma cell line SH-SY5Y was 
maintained at humidified air (95  %), 5  % CO2, 37  °C, 
and cultured in DMEM/F12 (Life Technologies, Darm-
stadt, Germany) supplemented with 10  % FCS and 1  % 
Glutamine (both GE Healthcare, Piscataway, NJ, USA). 
For assay conditions, cells were seeded at a density of 
30,000 cells per well of a white glas-bottom 96 well plate 
(Greiner Bio-One GmbH, Frickenhausen, Germany) in 
OptiMEM (Life Technologies, Darmstadt, Germany). 
After 24  h incubation period, culture supernatant 
was aspirated and exchanged by 50  µl fresh OptiMEM 
or OptiMEM supplemented with A-beta peptides in 
NH4OH/PBS at the indicated concentration or with sol-
vent. Cells were incubated for 24  h; subsequently, 5  µl 
cell supernatant for LDH release assay were pipetted to 
a clear 96 well plate and assay was performed as recom-
mended by the manufacturer (Biovision, Milpitas, CA, 
USA). 5 µl MTT (5 mg/ml, Sigma Aldrich, St. Louis, MO, 
USA) were added per well to the cells. Development of 
formazane crystals was controlled by light microscopy 
and crystals lysed after 1 h of incubation [humidified air 
(95 %), 5 % CO2 and 37 °C] with 200 µl 0.1 N HCl in iso-
propanol per well by vigorous pipetting. Then, absorp-
tion was measured at 595 and 620 nm in a plate reader 
(Asys Hitech Expert 96, Biochrom, Cambridge, UK) and 
viability calculated by A595–A620 in % of control (solvent-
treated cells).
In vitro fibrillization of A‑beta peptides
A-beta 42 peptides (132  µM) were fibrillized in a total 
volume of 25  µl 1xPBS for 24  h at 37  °C, 300  rpm in a 
thermomixer (Eppendorf AG, Hamburg, Germany). 
For the monomeric form, the buffer was incubated as 
described and A-beta was added immediately before 
preparation for western blotting.
Animals
Male C57Bl6/J, FVB/N or abcb1a/1b−/− mice (FVB/N 
background, Taconic, USA, [12]) and 5xFAD (Jackson 
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Laboratory; [13]) stably cross-bred with C57Bl6/J mice 
from the animal facility of the University Medical Center 
of Mainz were used (body weight 25–45 g). Animals were 
housed in groups of 2–5 with free access to food and 
water. A 12  h light–dark cycle (6  a.m.–6  p.m. light on) 
was maintained at a temperature of 22  °C and a relative 
humidity of 60 %.
Study design and drug administration
Intranasal administration
Acute treatment Mice received A-beta 42 peptides 
in both nostrils after mild i.p. chloralhydrate anesthe-
sia (0.006 ml/g bodyweight of a 7 % saline solution). Per 
administration maximally 5 µl solution at once were given 
with an intermission of 2  min to ensure proper breath-
ing and absorption of the A-beta-solution. Thus, mice 
received 10 µg A-beta 42 in total. To facilitate penetration 
into the CNS, mice were pre-treated with mannitol. Man-
nitol was injected i.p. at a dose of 0.03 ml/g bodyweight 
[14] 20 min prior to the A-beta application. For preven-
tion of A-beta degradation NEM (5 µl of 1 M NEM) was 
pipetted into each nostril 5 min prior to the first A-beta 
administration if indicated.
For fluorescence-signal based A-beta detection 
TAMRA-A-beta 42 (Anaspec, Seraing, Belgium) was 
administered as described above (5 µg per nostril). As a 
control, water in the appropriate volume supplemented 
with the dilution reagent from the vendor was used. 1 h 
after administration, animals were sacrificed and brains 
dissected in six slices (as given in Fig.  2b). Tissue was 
homogenized in 500 µl PBS per slice (Tissue lyzer, Qia-
gen, Hilden, Germany; 5 min 50 Hz), centrifuged at 4 °C 
500 g for 10 min and supernatant diluted 1:5 in PBS. 80 µl 
homogenate were supplemented to fluorescence meas-
urement (Exc 540/Em 580) in technical duplicates. Mean 
values obtained for respective tissue slice of the control 
treated animal were subtracted from the values from the 
A-beta treated mouse.
For immunohistochemistry, solvent or A-beta 42 
(Anaspec, Seraing, Belgium) were administered as 
described above (5 µg per nostril) and animals sacrificed 
1 h later.
Treatment for  behavioral investigations For analysis of 
behavioral effects, A-beta 42 peptides were administered 
for three consecutive days (day 1–3 of the MWM, day −1, 
1, and 2 of the fear conditioning). Mice were pre-treated 
with mannitol as described for the acute treatment. Sub-
sequently, A-beta/NH4OH/PBS-solution (10 µg peptide/
day) or NH4OH/PBS alone (controls) were pipetted into 
nostrils as described before [minimal number of animals 
(n) = 5 per group, indicated in the respective figure].
Preparation of brain homogenates
Animals from acute treatment experiments were sacri-
ficed 1 h after A-beta application under isoflurane anes-
thesia via decapitation. Brains were quickly removed and 
immediately stored on ice. If needed, tissue was stored at 
−80 °C until further use. Per hemisphere 400 µl ice cold 
homogenization buffer [20  mM Tris/HCl pH 8.5, sup-
plemented with protease inhibitor mix (Complete Mini, 
Roche, Mannheim, Germany)] were added and tissue 
homogenized for 10 min at 50 Hz in a pre-chilled swing 
mill (Tissue lyzer, Qiagen, Hilden Germany) using 5 mm 
pre-chilled stainless steel beads (Qiagen, Hilden Ger-
many). Homogenates were supplemented with formic 
acid (70  % final) and incubated at 4  °C for 1  h in a test 
tube rotator (GFL 3025, Burgwedel, Germany). Superna-
tant from ultracentrifugation (1 h 4 °C 35.000 rpm, rotor 
70.1 Ti, Beckman Coulter, Krefeld, Germany) was neu-
tralized with 20-fold volume of 1 M Tris. Protein content 
of samples was assessed by the method of Bradford (Roti-
NanoQuant, Carl Roth, Karlsruhe, Germany).
Western blotting
For tissue analysis, samples were adjusted with LDS 
NuPAGE buffer (1×, Life Technologies, Darmstadt, 
Germany) and DTT (1 M, 10 % v/v) to obtain 20 µg pro-
tein/15  µl and incubated for 10  min at 70  °C. Samples 
were subjected to 4–12  % NuPAGE gradient gel (Life 
Technologies, Darmstadt, Germany) using MES buffer 
and a voltage of max. 150  V. For in  vitro fibrillization 
analysis, peptide preparations were supplemented with 
LDS NuPAGE buffer (1×) and DTT (1 M, 10 % v/v) and 
boiled for 5 min at 95 °C. Samples were separated on 10 % 
SDS–polyacrylamide gels and blotted onto nitrocellulose 
membrane at 100  V for 2  h. Immunodetection of APP 
and A-beta was carried out by blocking the membranes 
for 1  h in blocking solution [0.2  % I-Block (Life Tech-
nologies, Darmstadt, Germany), 0.05 % Tween 20 (Appli-
Chem, Darmstadt, Germany) in PBS] and incubation 
overnight at 4 °C with antibody 6E10 (Covance, Munich, 
Germany) at a dilution of 1:1000 in blocking solution. 
Blots were incubated with anti-mouse secondary anti-
body coupled with horseradish peroxidase (Thermo 
Scientific, Karlsruhe, Germany) and signals obtained by 
applying SuperSignal West Femto chemiluminescent 
substrate (Thermo Scientific, Karlsruhe, Germany) were 
detected using a CCD-camera imaging system (Stella 
Camera, Raytest, Straubenhardt, Germany).
ELISA
Human A-beta 42 ELISA was performed as recommended 
by the manufacturer (IBL, Hamburg, Germany). Samples 
from a 5xFAD mouse brain were used as a positive control.
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Immunohistochemistry
Brains were dissected, washed with 0.9  % NaCl and 
immediately submerged in 4.5 % formalin for 24 h at RT. 
Subsequently, hemispheres were embedded in paraf-
fin at 58  °C and cut in 2  µm thick tissue sections using 
a rotary microtome (Leica RM 2245). After mounting 
on histological slides (Superfrost plus, Menzel), sections 
were stained following standard protocols using the pri-
mary antibody 6E10 (diluted 1:500 in Antigen Retrieval 
Buffer 1; Medac, Wedel, Germany) and DAB as the chro-
mogenic substrate. Microscopic pictures were taken with 
4 × 10 or 10 × 10 magnification (EVOS XL, Life Tech-
nologies, Darmstadt, Germany).
Morris water maze
Spatial learning and memory was tested by the Morris 
water maze hidden platform task in C57Bl6/J mice using 
the maze and protocol as described previously [15]. In 
brief, the platform stayed in the same quadrant for all tri-
als (South West) and the animals were released from four 
different positions at the pool perimeter. Mice performed 
four trials per day on five consecutive days with a maxi-
mum length of 60 s per trial and an inter-trial interval of 
90 s. Mice were allowed to stay on the platform for 10 s. 
On the sixth day, a probe trial (60 s) without platform was 
performed (starting position: North East). Learning was 
assessed by measuring the latency to find the platform. 
For characterization of memory the number of potential 
platform crossings and % of goal quadrant occupancy 
during the probe trial were assessed.
Fear conditioning
Fear memory was tested in an auditory fear conditioning 
task (see Fig. 3a) similarly to: [16]. Mice underwent three 
sessions: (1) A single conditioning session with one tone 
presentation (30 s, 9 kHz, 75 dB SPL, pulsed 5 Hz) end-
ing with an electric current (0.7 mA, 2 s, pulsed 25 Hz); 
(2) assessment of conditioned fear 24 h later in a context-
dependent retention test [180 s, same box and light con-
ditions as before (rectangular cage, 125  lx)], and (3) 2 h 
later in a tone-dependent retention test (180  s, 9  kHz, 
75  dB SPL, pulsed 5  Hz) with different context (round 
cage, plane floor, 500 lx).
Monitoring of behavior
For the Morris water maze task a computerized video 
system registered moving-path and duration automati-
cally. The hardware consisted of an IBM-type AT com-
puter combined with a video digitizer and a CCD video 
camera. The software used for data acquisition and 
analysis was EthoVision XT release 8.5 (Noldus Infor-
mation Technology, Utrecht, Netherlands). In case of 
fear conditioning, the experiments were performed in 
a computerized fear-conditioning system where activ-
ity of the animal is recognized by infrared laser beams 
(TSE-Systems, Bad Homburg, Germany). During training 
and context-dependent retention test, mice were placed 
in a Plexiglas cage (context 1; 20 × 20 × 40 cm). Tone-
dependent retention tests were performed 2  h after the 
contextual memory test in a novel context (context 2). 
Context 2 was a circular Plexiglas cage with 19.0  cm in 
diameter and 40.0 cm in height. Grid floor was covered 
by a grey plastic bottom and light level was changed as 
mentioned above. The fear conditioning box was thor-
oughly cleaned with 70  % ethanol before the placement 
of each mouse.
Quantification and statistical analysis
Data were analyzed by using GraphPad Prism 6 (Graph 
Pad Software, La Jolla, CA, USA) or SPSS (IBM, Ehnin-
gen, Germany). Cell culture experiments were statistically 
analyzed by one-way ANOVA followed by Bonferroni 
multiple comparisons test. For the behavioral studies, 
data were analyzed by ANOVA for differences between 
the treatment conditions. Multivariate analysis of vari-
ance (two-way ANOVA) was performed for learning and 
memory testing. Probe trial scores within experimental 
groups were evaluated by a one-way ANOVA. Post hoc 
comparisons of the treatment were based on Student’s t 
test, difference to chance levels in quadrant occupancy by 
one sample t test. Differences were considered significant 
for p ≤ 0.05.
Results
The aim of our study was to investigate if application of 
A-beta 42 peptides via the nasal cavity is able to evolve 
lesions within the mouse brain that lead to changes in 
learning and memory performance. Initially, we tested 
the peptides used in our animal study for their capabil-
ity of evoking toxic effects on neuronal cells. A 24  h 
treatment period of human neuroblastoma cell line SH-
SY5Y with 1 µM monomeric peptides resulted in about 
20  % reduction of viability as compared to control cells 
(Fig. 1a, left graph). This was accompanied by an increase 
of 30  % of LDH in the cell supernatant (Fig.  1a, right 
graph), indicating the toxic characteristic of peptide 
preparation. With 5  µM we observed reduced viability 
of only 90 % compared to control and only in tendency 
enhanced secretion of LDH into the medium. This might 
be due to the fact that A-beta accumulates at higher dos-
age in the endosomal/lysosomal compartment as well as 
on the cell surface and is able to interfere in a toxicity-
independent manner with both, the reduction reaction 
and integrity of the membrane (e.g. [17, 18]).
Next, we wanted to demonstrate the ability of the pep-
tides used to form higher molecular weight species at 
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physiological temperature and buffer conditions. Upon 
24  h incubation at 37  °C under agitation most of the 
monomeric peptide was included in oligomeric forms 
or protein species with up to about 250 kDa (exemplary 
western blot; Fig.  1b) which represent large aggregates 
[19]. Subsequently, we wanted to investigate, if intrana-
sally administered A-beta peptides might be detectable 
after acute treatment in the brain. In Alzheimer model 
mice (Fig. 2a 5xFAD, [13, 20]), which were used for com-
parison, a weak band for what might represent residual 
full-length APP from extraction and a strong band for 
monomeric A-beta were detected. Both were absent in 
wild type mice only expressing endogenous murine APP. 
In wild type mice treated with A-beta via nasal route 
and the degradation inhibitor N-ethylmaleimide (NEM, 
[21]) alone, no bands corresponding to the exogenously 
administered A-beta peptides were observed. As it has 
been described that A-beta might be efficiently elimi-
nated from brain via P-glycoprotein (P-gp [22]), the main 
export transporter of the blood brain barrier, we tested 
P-gp knock-out mice for a potential detectable accumu-
lation of the exogenous peptides in brain tissue. Simi-
larly to the NEM treated wild type, no additional bands 
occurred in western blotting experiments. Only sam-
ples from mice pre-treated with mannitol, which relaxes 
blood–brain barrier after i.p. injection [14], showed 
bands detectable with antibody 6E10 that might reflect 
A-beta aggregation products after tissue extraction: e.g. 
a band of about 25  kDa that is also present in 5xFAD 
mouse brain tissue preparation but not in untreated wild 
type mice was visible (Fig. 2a, arrows). In regard to the 
fact, that tissue spiked with monomeric A-beta showed 
only about 30  % of the expected signal derived from 
A-beta incubated without tissue, retrieval rate is rather 
low and might severely impair A-beta detection without 
further labeling of the peptide (Fig. 2a, lane s compared 
to lane iv). In sum, we decided to pre-treat mice with 
mannitol before nasal delivery of A-beta 42 peptides 
in behavioral testing. To demonstrate the potential of 
A-beta peptides to enter also deeper regions of the brain 
after intranasal application, we treated an exemplary 
wild type mouse with TAMRA-labeled A-beta 42 and a 
control mouse with solvent and investigated six different 
slices obtained from the brains according to fluorescence 
signal: the highest fluorescence intensity was obtained 
from a slice containing cortical regions (2, Fig. 2b). The 
lowest signal was measured from samples derived from 
Tectum/Tegmentum region but fluorescence was detect-
able throughout the brain also reaching cerebellar tissue 
(6, Fig. 2b). This indicates that the fluorescence-labeled 
peptide enters the brain and is present in brain regions 
needed for learning and memory function already 
shortly after application. We therefore assume that also 
the unlabeled peptides would be delivered in analogy 
and therefore have an impact on brain function. To make 
sure that not only the fluorophore is delivered through-
out the brain but also the coupled peptide, we performed 
ELISA targeting the exogenously administered human 
A-beta 42 and obtained values ranging from about 
700 pg/ml in the first two slices down to 15 pg/ml after 
correction for untreated control background (Additional 
file 1).
a b
Fig. 1 Characteristics of A-beta 42 peptides in vitro. a SH-SY5Y cells were treated for 24 h with A-beta 42 peptides, solvent (control) or pure culture 
medium (untreated). Cell viability was assessed by MTT assay (left graph) and by LDH release analysis (right graph). Values were calculated as % of 
control cells and are represented as mean and SD from three independent experiments (conducted in at least duplicate, n ≥ 6 as indicated). Signifi-
cant differences between solvent-treated controls and A-beta 42 treated cells (one-way Anova, Bonferroni’s multiple comparisons test) are indicated 
by *(p < 0.05) and ***(p < 0.001). b A-beta peptides were incubated at 37 °C for 24 h under agitation in PBS (fibrillated, f ). As controls, untreated 
A-beta 42 peptides (monomeric, m) and buffer with unrelated protein (trypsin, −) were used. 7.4 µg of protein each were subjected to 10 % SDS–
polyacrylamide gel, transferred to nitrocellulose and detected with antibody 6E10 and anti-mouse horse radish-labeled secondary antibody
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Additionally, we stained sagittal brain sections from 
wild type C57B6/J mice sacrificed 1  h after transna-
sal delivery of A-beta 42 peptides with antibody 6E10 
(Fig. 2c). A 4 month old 5xFAD mouse served as a posi-
tive control and showed cortical as well as even more 
pronounced staining of the hippocampus, while analysis 
of secondary antibody control and the respective wild 
type littermate did not result in specific staining signals. 
In the peptide-treated animal (i.n., Fig.  2c), no distinct 
deposits as observed in the genetic AD model occurred. 
However, brain slices seemed to display a slight increase 
in overall diffuse staining as shown for hippocampal as 
well as cerebellar region, indicating presence of antigen.
For in  vivo effects of intranasal A-beta 42 we investi-
gated its potential influence on learning and memory in 
two different laboratory mouse strains. At first we stud-
ied behavior in a fear conditioning task with respect to 
context- and cue-retention. FVB/N mice treated with 
a c
b
Fig. 2 Detection of A-beta 42 peptides within brain after intranasal acute application. a Mice (wt: FVB/N; ko; Pgp knock-out) were treated with 
NEM and mannitol as indicated. Subsequently, A-beta was intranasally administered and animals were sacrificed after 1 h. Brains were dissected 
and proteins extracted by formic acid treatment. 20 µg of proteins were subjected to 4–12 % SDS–polyacrylamide gel and transferred to nitrocel-
lulose membrane. Signals were obtained as described in Fig. 1. As a control, brain extracts from a 5xFAD Alzheimer model mouse (AD) and the 
corresponding wild type littermates (wt, C57B6/J) were used (aged 9 months). Additionally, pure A-beta (in vitro, iv) and wild type brain spiked 
with A-beta during the extraction process (s) were analyzed. A band potentially representing A-beta oligomers from the 5xFAD or A-beta/mannitol 
treated animal is depicted by an arrow. Unspecific signals that also occur in a “secondary antibody only” incubation (Additional file 2) are indicated 
by curly brackets). b For assessment of A-beta distribution upon intranasal delivery, 10 µg of TAMRA-labeled A-beta 42 peptide or water in diluent 
solution (control) were administered to C57Bl6/J wt mice pre-treated with mannitol (one exemplary animal for each treatment). 1 h after the appli-
cation, slices from brains (cut positions indicated in the scheme) were used for detection of light emission at 580 nm in technical replicates of tissue 
homogenates. RFU (relative fluorescence units) were calculated by substracting values obtained from TAMRA-A-beta 42 treated animal by values 
measured for the control animal (mean and SD). c To analyze distribution of intranasally administered A-beta 42 peptides, animals were treated 
as described in B with unlabeled A-beta 42 peptide (i.n.) or solvent (control) and brains dissected 1 h after treatment. Staining of sagittal sections 
was performed with primary antibody 6E10. For comparison, a “secondary antibody only” staining (2°Ab) and samples from a wild type as well as a 
5xFAD transgenic mouse (4 months of age) are shown. An overview of the midbrain region of intranasally treated mice is given (4 × 10 magnifica-
tion) as well as hippocampal (H) and cerebellar (C) region in higher magnification (10 × 10)
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A-beta 42 were significantly impaired compared to sol-
vent treated controls in the cue-retention condition 
(Fig.  3b). Freezing-reaction after tone presentation was 
about 1.5 times lower in A-beta treated mice indicating 
a significant deficit due to the treatment. Control mice 
did not show appropriate freezing behavior in context-
retention under the chosen experimental parameters. 
This is consistent with former reports [23, 24] and might 
rely on presence of mutations in the Pde6b or deletion 
in the CP49 gene (implicated in retinal degeneration or 
establishing of lens fiber network) in this strain [25, 26]. 
Therefore, changes due to peptide-treatment in context-
conditioning were not measurable in FVB/N mice. To 
make sure that impaired behavior based on A-beta treat-
ment is not restricted to a single genetic background, 
we also included another commonly used mouse strain 
which is most often the background of transgenic Alz-
heimer model mice: C57Bl6/J mice treated with A-beta 
42 showed a strong impairment in the context-retention 
condition by a reduction of freezing time compared to 
controls of about 50  % (Fig.  3c). However, in the cue-
condition no significant difference was seen (control: 
33.37±6.51 %; A-beta 42: 34.37±5.71 %; p =  0.921) but 
freezing of control mice also appeared weaker due to 
tone presentation than due to context (p = 0.059). Such 
peculiarities regarding behavioral tasks have already been 
reported in literature for different mouse strains [27].
Another behavioral domain characteristically impaired 
in Alzheimer model mice is the spatial memory investi-
gated by the Morris water maze task (MWM, [28]). Due 
to the fact that FVB/N mice were known to be unsuit-
able in this task [23] we restricted the investigation to the 
C57Bl6/J strain. With respect to activity of the mice while 
performing the MWM task no differences between treat-
ment conditions were seen (swim speed: 13.0  cm/s in 
control mice; 12.4 cm/s in A-beta treated mice; p = 0.72) 
allowing for evaluation of cognitive performance. With 
respect to spatial orientation, untreated mice were able 
a
b c
Fig. 3 Impact of transnasally delivered A-beta peptides on fear conditioning memory. a Schematic representation of the fear conditioning experi-
ments with stimulus sequences, and variable training-test intervals. Animals were treated for three consecutive days with A-beta 42 peptides 
administered to the nose or with solvent control. On the second application day, mice underwent one training session with 180 s habituation, 
presentation of the conditioned stimulus (CS, tone, 30 s) with a mild foot shock within the last two seconds (US: unconditioned stimulus). The fol-
lowing day (third treatment day), mice were subjected to (1) context-dependent retention test (similar test situation without any stimulus), and (2) 
tone-dependent retention test (new context with CS presentation). b Cue-dependent fear conditioning related analysis in FVB/N mice either with 
A-beta 42 (black bar) or solvent treatment (white bar). The diagram represents total time of freezing behavior in the conditioned stimulus presenta-
tion (in %) ± SEM (n = 5 for each group) (**p < 0.01). c Fear conditioning related analysis in C57Bl6/J mice treated with A-beta 42 peptides (black 
bars, n = 7) or control animals (white bars, n = 13). The diagram represents total time of freezing behavior (%) ± SEM. Significant effects (p < 0.01) 
are indicated by **
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to learn the position of the submerged platform within 
5  days indicated by a significant reduction in time to 
reach the platform. A-beta 42 treated mice were also 
able in general to improve over the 5 days training period 
(Fig.  4a) but exhibited deficits in finding the platform 
indicated by a significant impairment on days two, three 
and five. The significance of the interaction term of a 
two-way ANOVA (AxB F(4,88) = 2.59; p = 0.05) displayed 
the impact of A-beta treatment as the learning devel-
oped differentially as compared to control mice [two-way 
ANOVA, factor A time, F(4,88) = 26.49; p < 0.0001, factor 
B treatment F(1,22) = 10.84; p = 0.01].
While in control mice time to reach the platform 
decreased from 46.83  ±  4.95 to 10.16  ±  2.17  s within 
the 5 days; the mice receiving intranasal A-beta 42 treat-
ment needed at each of the four time points at least 
24.71 ±  4.88  s to find the submerged platform. Similar 
results have been reported age-dependently for mice that 
harbor diffuse beta-amyloid deposits but do not form 
plaques [29]. For investigation of memory performance, 
the platform was removed and similar as during learn-
ing behavior, A-beta 42-treated mice needed significantly 
longer swimming times to find the former platform loca-
tion (data for day 6 not shown). The number of crossings 
of the supposed and former platform location was also 
reduced in A-beta-treated animals but did not reach sta-
tistical significance (Fig.  4b). However, when analyzing 
time spent in the respective quadrants, which is indica-
tive of memorizing its location dwell times above chance 
level in the goal quadrant were only seen in solvent-
treated mice (Fig. 4b). This indicates that A-beta-treated 
mice were not able to recall the position of the platform 
properly. Both behavioral aspects—fear conditioning as 
well as Morris-water maze learning—have been dem-
onstrated earlier to be A-beta sensitive [30–32]. When 
brain hemispheres of mice from behavioral tasks were 
subsequently used for A-beta 42 ELISA, no detectable 
amount above background signal was measured in sam-
ples derived from peptide treated mice (Additional file 3). 
We therefore have to assume that although peptides were 
probably already cleared from the brain after the behav-
ioral tests, they were able to induce cellular reactions 
during the 3  days of treatment that in consequence led 
to behavioral impairment. Similar findings have been 
reported for alteration of ERK signaling upon local brain 
infusion with A-beta 42 peptides [33].
Discussion
Confirmed post mortem AD pathology shows accumula-
tion of extracellular A-beta in plaques and intracellular 
neurofibrillary tau tangles in the brain. The involvement 
of A-beta in AD is a prerequisite to the significance of 
peptide production or clearance to AD. It should be 
noted that A-beta is a naturally occurring endogenous 
peptide that may have normal physiological functions. 
For example, it has been shown that picomolar concen-
trations of A-beta increased LTP resulting in improved 
synaptic plasticity and memory [34–36]. Therefore, 
pathology associated with A-beta has to be related to its 
aberrant accumulation/aggregation. Familial forms of 
early-onset AD are caused by mutations in APP, PS1, or 
PS2 (for a personal view on the discovery of those genes 
see [37]) or through increased copy number of APP 
[38–40]. This enabled pre-clinical research to establish 
a b
Fig. 4 Influence of intransally administered A-beta peptides on Morris water maze task in C57B6/J mice. a Learning during training days one to five 
is displayed by the time to find the submerged platform for mice treated with A-beta 42 peptides (closed circles, n = 10) or with solvent (open circles, 
n = 14) Significant daily differences (Student’s t test) are indicated by *(p < 0.05) and ***(p < 0.001). b Memory related behavior based on crossing 
the former platform location or time spent in the quadrant searching the platform at the probe trial (day 6). Crossings are given as total numbers 
(Student’s t test; *p < 0.05, left part of the graph) and time spent in the respective quadrant (NE North East, SE South East, SW South West, NW North 
West) is given in % of total time (60 s). White bars represent group mean ± SEM of control-treated animals whereas black bars represent values 
obtained for A-beta 42 peptide treated animals (*p < 0.05; **p < 0.01, one-way ANOVA, Sidak’s multiple comparisons test; #p < 0.05 indicates dwell 
times above chance level (25 %) one sample t test)
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multiple animal models that display various functional 
deficits either related to tau or A-beta pathology at vari-
ous stages and age [2]. While the familial genetics clearly 
point to A-beta as a critical factor in the etiology of AD, 
it is conceivable that the much more common sporadic 
form of the disease (i.e., LOAD) has a distinct origin 
potentially independent from A-beta production. Nev-
ertheless, several lines of evidence suggest otherwise [41, 
42]. The differences between FAD and LOAD made it dif-
ficult for pre-clinical research in development of animal 
models to investigate mechanisms underlying LOAD. 
Some animal species such as aging Octodon degu or pri-
mates spontaneously develop AD pathology indicated 
by plaques or tauopathy (reviewed in [43]) but research 
in those models is restricted due to economic as well as 
ethical reasons. Exogenous administration of A-beta 
in rodent brain resulted in different outcomes, depend-
ing for example on site of application [44, 45]. Various 
approaches have been made with A-beta elevating drugs 
or modulators of tauopathies to establish spontaneous 
AD models: for example slow injection of thiorphan, 
a neprilysin inhibitor, by a osmotic minipump into the 
hippocampus led to decrease in learning and memory 
performance in rats after 4  weeks [46]. Administration 
of Wortmannin, an activator of GSK3beta, in the lateral 
ventricle of rats resulted in hyperphosphorylation of tau 
[47]. As thiorphan is able to inhibit not only A-beta deg-
radation but also that of endogenous enkephalins [48] 
and Wortmannin acts via PI3 kinase/PKB/Akt pathway 
(short overview in [49]), side effects apart from direct 
interference with Alzheimer-related targets have to be 
considered in such efforts.
Our approach presented here provides good evidence 
for the investigation of A-beta 42 mediated deficits not 
caused by genetic pre-disposition, after surgical manipu-
lation or by treatment with pharmacological compounds 
with potential side effects. Intranasal application has 
been shown several times to be a painless, harmless way 
to deliver biologics or treat disease related symptoms 
(overview in: [50]). An intranasally administered antibody 
against A-beta peptides was found to penetrate the brain 
within 2 h and to spread throughout the brain within 12 h 
post injection [51]. Detection of the HRP-labeled anti-
body within the brain parenchyma was observed as early 
as 6 h post injection in the vicinity of the 3rd ventricle, 
midbrain and hippocampus in these experiments. How-
ever, the peptide we used here is obviously smaller and 
we pre-treated animals with mannitol. Delivery of drugs 
via the nose has been reported to generally circumvent 
the blood brain barrier which is transiently disrupted by 
treatment with hyperosmolaric sugar solutions such as 
mannitol. Nevertheless, effects of mannitol on nasal and 
airway epithelium has been described that might further 
support entry of the peptide into the brain [52–54]. As 
the animals were not perfused in our study prior to tissue 
harvesting, we cannot rule out in principle that observed 
signals for native or fluorophore-labelled A-beta peptides 
might derive from blood comprised in tissue homogen-
ates. Intravenously injected Cy5.5 labelled A-beta 40 for 
instance colocalized with UEA-1 stained cerebral vessels 
8 h post injection [55].
However, functional deficits in two learning- and mem-
ory-related behavioral tasks pointed towards the efficacy 
of intranasal treatment with A-beta 42. Likewise genetic 
FAD mouse models [56] mice in our study displayed 
deficits in MWM as well as in fear conditioning. A-beta 
42 had a significant impact on hippocampus-dependent 
spatial learning and memory and context-dependent fear 
conditioning (Figs.  3c, 4; [57, 58]) and additional amyg-
dala-related memory function (Fig.  3b; [58, 59]) as has 
been shown in FAD mouse models [56]. Those deficits 
were already visible after 3  days of treatment with the 
peptide while in AD transgenic model mice behavioral 
deficits occur mostly after plaque deposition at an earli-
est time point of 1–2 months of age [2]. In an AD mouse 
model with genetic cause of origin, it has been reported 
that plaques are able to grow within 24 h and elicit local 
microglia activation within 1–2  days [60]. In our study, 
we administered 10  µg A-beta 42 daily which theoreti-
cally would result in a concentration of about 30 ng pep-
tide per mg tissue and thus is three times higher than 
levels found in the double transgenic APP/PS1 mouse 
model (e.g. [61]). Taking into account that A-beta is 
quickly removed from brain via transporters of the blood 
brain barrier or degradation (half life time of 2 h reported 
in [62]) and probably not all peptide is resorbed via the 
nasal epithelium, we would assume that effective A-beta 
levels in the brain were in fact lower and observed effects 
are based mainly on soluble A-beta species. In this regard 
it would be of interest, if A-beta 40 and 42 would differ 
in outcome intensities of behavioral effects because clear-
ance of the 40 amino acid peptide from brain tissue has 
been described to be faster after ivc [63] and also archi-
tecture of fibrils and plaques differ in between both pep-
tide species [64].
In sum, our model allows investigation of acute A-beta 
dependent influences within the brain. Nevertheless, 
it has its limitations due to the fact that sporadic AD 
develops over decades within human life [65]. This has 
consequences regarding e.g. long-term inflammatory 
events, occurrence of compensatory mechanisms or even 
brain atrophy at later stages that might obviously not be 
observed in such a model of direct application. Addition-
ally, our treatment might not reflect routes of spreading 
characteristic for spontaneous AD. Intranasal admin-
istration utilizes three main delivering pathways for 
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material to the brain: the olfactory [66], the rostral migra-
tory stream [67], and trigeminal routes (e.g. [68]). This in 
consequence leads to a fast delivery that nearly targets 
all brain areas from olfactory bulbs throughout the hind-
brain. In AD, the commonly-received concept assumes 
an origin within the transentorhinal and entorhinal cor-
tex from where pathology spreads slowly throughout the 
entire brain. Additionally, within the last years, propaga-
tion of AD pathology via a neuronal cell-to-cell transfer 
has been suggested by cell culture and animal experi-
ments [69, 70]. In transnasal delivery, however, trans-
neuronal and para-neuronal pathways seem to contribute 
depending on the administered drug formulation [71]. As 
we did not investigate the spreading of the exogenously 
applied peptides within the brain further, we cannot 
speculate yet on the route taken.
Conclusions
In sum, our results seem promising regarding a model for 
acute alterations caused by A-beta peptides in the mouse 
that might have the potential to mimic aspects of LOAD. 
Nevertheless, there remain some questions in regard to 
optimal dosage, treatment duration, age of treatment 
onset, efficacy of epithelial transport and multiple other 
effects of intranasal delivery of A-beta 42, which have to 
be answered in future investigations.
Additional files
Additional file 1:  Analysis of A-beta 42 peptides from acute trans-
nasally treated mice. An exemplary wild type animal was treated with 
TAMRA-labeled A-beta 42 peptides and a control mouse with solvent 
administered to the nose (see Figure 2B). Brains were dissected 1 h later 
and homogenized as described. Extraction supernatant was subjected 
to human A-beta 42 ELISA (IBL) as recommended by the vendor. Values 
obtained for A-beta 42 containing slices were corrected for background 
values obtained from slices of solvent-control. Note that signal intensities 
for the six slices deviate from the fluorescence-based A-beta 42 measure-
ment. This might indicate a partial liberation of the fluorophore from the 
peptide or be due to interference of tissue contents with the two different 
measurement techniques. Nevertheless, human A-beta 42 peptides were 
detectable throughout all of the six slices upon intranasal application also 
by peptide-directed ELISA.
Additional file 2:  Specificity control for antibody 6E10. 20 μg of proteins 
from brain tissue of wt or AD model mouse (5xFAD) were subjected to 
4-12 % SDSpolyacrylamide gel and transferred to nitrocellulose mem-
brane. Signals were obtained by combining antibody 6E10 and secondary 
HRP-coupled antibody (left) or by secondary antibody only (right).
Additional file 3:  Analysis of A-beta 42 peptides from transnasally 
treated mice. Animals were treated for three consecutive days with A-beta 
42 peptides administered to the nose or with solvent control. Brains were 
dissected after behavioral task performance of the mice, stored at -80 °C 
and extracted with 70 % formic acid. 100 μl extraction supernatant from 
solvent (n = 3) or peptide-treated (n = 4) mice were subjected to human 
A-beta 42 ELISA (IBL) as recommended by the vendor. All measured values 
were at or below the lowest standard (red dots). As a positive control we 
used brain extract from an age-matched 5xFAD mouse (green triangle).
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